-
21.发明公开
公开(公告)号：EP1345604A1
公开(公告)日：2003-09-24
申请号：EP01986259.8
申请日：2001-09-21
IPC分类号： A61K31/40 , C07D403/14
CPC分类号： A61K31/40
摘要： The present invention relates to an administration schedule comprising the intravenous administration of a α-halogen-acryloyl distamycin derivative, or a pharmaceutically acceptable salt thereof. The above administration allows the treatment of a variety of tumors in mammals.
-
22.发明公开Combined preparations comprising anthracycline derivatives 有权Kombinationspräparatenthaltend ein Morpholinyl Anthracyclinderivat und einen Topoisomerase II Inhibitor
公开(公告)号：EP1323423A1
公开(公告)日：2003-07-02
申请号：EP03075776.9
申请日：2000-04-04
IPC分类号： A61K31/70 , A61K31/675
CPC分类号： A61K45/06 , A61K31/675 , A61K31/70 , A61K2300/00
摘要： The present invention relates to combined preparations comprising a morpholinyl anthracycline administered in combination anticancer agents chosen from an alkylating agent, an antimetabolite, a topoisomerase II inhibitor, a topoisomerase I inhibitor and an antimitotic drug, which are useful anticancer therapy, particularly in the treatment of a primary or metastatic liver cancer.
摘要翻译： 本发明涉及包含作为有用的抗癌治疗的选自烷化剂，抗代谢物，拓扑异构酶II抑制剂，拓扑异构酶I抑制剂和抗有丝分裂药物的组合抗癌剂中的吗啉基蒽环霉素的组合制剂，特别是在治疗 原发性或转移性肝癌。
-
23.发明授权SULFURATED DISTAMYCIN DERIVATIVES, PROCESS FOR PREPARING THEM, AND THEIR USE AS ANTITUMOR AGENTS 有权含硫醚偏端霉素衍生物，用于生产及其作为抗肿瘤药
公开(公告)号：EP1100777B1
公开(公告)日：2003-05-28
申请号：EP99936609.9
申请日：1999-07-21
IPC分类号： C07D207/34 , A61K31/40
CPC分类号： C07D207/34
-
-
25.发明公开COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND ALKYLATING AGENTS 有权基于偏端霉素ACRYLOYLDERIVATEN和烷化剂联合肿瘤的治疗
公开(公告)号：EP1303307A2
公开(公告)日：2003-04-23
申请号：EP01960355.4
申请日：2001-06-20
IPC分类号： A61K45/06
CPC分类号： A61K45/06
摘要： Compounds which are alpha-halogenoacryloyl distamycin derivatives of formula (I) wherein R1 is a bromine or chlorine atom; R2 is a distamycin or distamycin-like framework as set forth in the specification; or a pharmaceutically acceptable salt thereof; are cytotoxic agents particularly effective in the treatment of tumors over expressing GSH/GSTs system and which are poorly responsive or even resistant to conventional antitumor therapies.
-
公开(公告)号：EP0970098B1
公开(公告)日：2003-03-12
申请号：EP98964472.9
申请日：1998-11-27
发明人： PORTELLO, Cinzia , ARLANDINI, Emanuele , BREME, Umberto , COLOMBO, Anna, Luisa , FRANCHI, Giuliano , ORONZO, Giuliano , TATO', Marco , GAROFANO, Luisa , CIOMEI, Marina
IPC分类号： C07H15/252 , A61K31/70 , C12P19/56
CPC分类号： C07H15/252
摘要： Anthracycline glycosides of formula (I) wherein R represents one of the two residues (a) or (b), and pharmaceutically acceptable salts thereof are anti-tumor agents.
-
公开(公告)号：EP1280803A1
公开(公告)日：2003-02-05
申请号：EP01915373.3
申请日：2001-03-19
IPC分类号： C07D457/06
CPC分类号： C07D457/06
摘要： Crystalline form II of cabergoline, a pharmaceutical composition containing it and a process for its preparation are disclosed. The process may comprise crystallization from a solution of raw cabergoline in an organic solvent at low temperatures or submitting to a slurry procedure a mixture of cabergoline Forms I and II in a solvent at a temperature below about 30 °C.
-
公开(公告)号：EP1272489A1
公开(公告)日：2003-01-08
申请号：EP01936098.1
申请日：2001-03-19
申请人： Pharmacia Italia S.p.A. , Tomasi, Attilio , Magenes, Stefania , Ungari, Mario , Ramella, Giuliano , Pallanza, Gianfranco
IPC分类号： C07D457/04
CPC分类号： C07D457/04
摘要： A process for producing crystalline form I of cabergoline, which process comprises crystallization of the desired form from a toluene/diethyl ether mixture comprising raw cabergoline, followed by recovery and drying of the resulting crystals. A new solvate form V of cabergoline, useful as an intermediate, is also provided.
-
29.发明公开METHOD TO POTENTIATE THE THERAPEUTIC EFFICACY OF TAXANE AND DERIVATIVES THEREOF 审中-公开法增TAXAN的疗效及其衍生物
公开(公告)号：EP1267889A1
公开(公告)日：2003-01-02
申请号：EP01902382.9
申请日：2001-02-01
IPC分类号： A61K31/66 , A61K31/335 , A61P35/00
CPC分类号： A61K45/06 , A61K31/335 , A61K31/565 , A61K2300/00
摘要： The use of estramustine phosphate and its metabolites estramustine and estromustine allow to potentiate the therapeutic efficacy of taxanes by both improving their pharmacokinetic and pharmacodynamic profile through the inhibition of (CYP)2C8 and (CYP)3A4 enzymes, both responsible for the metabolism of the taxanes; formulations of estramustine phosphate and metabolites, combinations of these latter with taxanes and therapeutic methods of treatment comprising them as a combined therapy are also disclosed.
-
公开(公告)号：EP0722446B1
公开(公告)日：2002-12-11
申请号：EP95926927.5
申请日：1995-07-18
IPC分类号： C07D403/14 , C07D417/14 , A61K31/40
CPC分类号： C07D231/38 , C07D403/14 , C07D417/14
-
-
-
-
-
-
-
-
-
搜索结果
175 条记录 (耗时 0.018 秒)
